Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: A retrospective study from a US academic medical center-Reference-Cited by-同舟云学术

Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: A retrospective study from a US academic medical center

Published:2021-03 Issue:3 Volume:84 Page:830-833
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Daniel Vijaya T.,Blankenship Kaitlin C.,Daly Robert F.,Tkachenko Elizabeth,Morss-Walton Peyton C.,Levin Nikki A.

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. Utility of repeat latent tuberculosis testing with QuantiFERON-TB Gold test in patients with psoriasis treated with tumor necrosis factor- α inhibitors at a single US institution;Ya;Br J Dermatol,2020

2. The seroconversion rate of QuantiFERON-TB Gold in-tube test for psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin 17A monoclonal antibodies;Wu;PLoS ONE,2019

3. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics;Menter;J Am Acad Dermatol,2019

4. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

5. Tuberculosis test usage and medical expenditures from outpatient insurance claims data, 2013;Owusu-Edusei;Tuberc Res Treat,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China;Dermatology and Therapy;2022-05-26

2. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection;Journal of Dermatological Treatment;2022-04-11

3. Adalimumab/ustekinumab;Reactions Weekly;2021-03

4. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL ‐17 inhibitors? A cohort study;Dermatologic Therapy;2020-11